Sugi Predict

Sugi Predict / Targets / GRIA1

GRIA1

Glutamate receptor 1 · P42261 · GRIA1 on Sugi Atlas →

54,680 patent compounds predicted against GRIA1, 30,446 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Quisqualate Quisqualate (SCHEMBL136819) 0.45 9/20
Nbqx Nbqx (SCHEMBL120375) 1.00 8/20
Gusperimus Gusperimus (SCHEMBL26925) 0.46 8/20
Gusperimus Gusperimus (SCHEMBL317327) 0.46 8/20
Gusperimus Gusperimus (SCHEMBL317912) 0.46 8/20
SCHEMBL275641 SCHEMBL275641 0.46 6/20
SCHEMBL28559 SCHEMBL28559 0.45 6/20
SCHEMBL28560 SCHEMBL28560 0.45 6/20
SCHEMBL306050 SCHEMBL306050 0.44 6/20
(R,S)-Ampa (R,S)-Ampa (SCHEMBL68799) 0.69 5/20
SCHEMBL240780 SCHEMBL240780 0.53 5/20
SCHEMBL43843 SCHEMBL43843 0.44 5/20
SCHEMBL158168 SCHEMBL158168 0.44 5/20
Mimosine Mimosine (SCHEMBL41924) 0.42 5/20
L-Mimosine L-Mimosine (SCHEMBL41925) 0.42 5/20
SCHEMBL147252 SCHEMBL147252 0.65 4/20
SCHEMBL121942 SCHEMBL121942 0.64 4/20
SCHEMBL195083 SCHEMBL195083 0.61 4/20
SCHEMBL92048 SCHEMBL92048 0.48 4/20
SCHEMBL38535 SCHEMBL38535 0.47 4/20

Clinical trials — most relevant to GRIA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy PHASE4COMPLETED
Ketamine Treatment Effects on Synaptic Plasticity in Depression PHASE4COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia PHASE3UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer PHASE1WITHDRAWN
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression EARLY_PHASE1RECRUITING
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Acamprosate: Genes Associated With Response nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome nanUNKNOWN
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus nanCOMPLETED
Regulation of Arginine-vasopressin (AVP) nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers nanCOMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIA1 binder may also engage these)

ProteinNameSimilarity
Q38PU8 — 1.000 Q38PU8 →
Q9Z2W8 — 1.000 Q9Z2W8 →
P19490 — 1.000 P19490 →
GRIA2 Glutamate receptor 2 1.000 landscape →
P23818 — 1.000 P23818 →
GRIA4 Glutamate receptor 4 1.000 landscape →
P23819 — 1.000 P23819 →
P19492 — 1.000 P19492 →
Q5R4M0 — 1.000 Q5R4M0 →
Q38PU5 — 1.000 Q38PU5 →
P19491 — 1.000 P19491 →
GRIA3 Glutamate receptor 3 1.000 landscape →
GRIK3 Glutamate receptor ionotropic, kainate 3 1.000 landscape →
P19493 — 0.999 P19493 →
Q38PU7 — 0.999 Q38PU7 →
Q9Z2W9 — 0.998 Q9Z2W9 →
Q38PU6 — 0.998 Q38PU6 →
Q38PU2 — 0.997 Q38PU2 →
B1AS29 — 0.997 B1AS29 →
P42264 — 0.997 P42264 →
Q38PU4 — 0.996 Q38PU4 →
P42260 — 0.996 P42260 →
P39087 — 0.995 P39087 →
Q91755 — 0.995 Q91755 →
Q38PU3 — 0.994 Q38PU3 →
GRIK2 Glutamate receptor ionotropic, kainate 2 0.993 landscape →
B4KD90 — 0.992 B4KD90 →
P26591 — 0.991 P26591 →
A0A2R8QF68 — 0.991 A0A2R8QF68 →
GRIK1 Glutamate receptor ionotropic, kainate 1 0.990 landscape →